Connect with us

Finance

Zuckerberg-backed rare disease platform RDMD raises $3 million in seed funding

Published

on



RDMD co-founders
RDMD
co-founders Nancy Yu and Onno Faber.

RDMD


  • RDMD is a platform for data sharing between patients
    with rare diseases, doctors, and researchers.
  • The company announced on Monday it har raised $3
    million in seed funding led by Lux
    Capital
     and Village
    Global
    , whose network of backers include Bill Gates,
    Mark Zuckerberg, Jeff Bezos, and Reid Hoffman.

When Onno Faber was diagnosed in 2014 with a rare disease called
neurofibromatosis type 2 that creates tumors in the central
nervous system, he blindly combed through the Internet for
treatment options before a friend who was doing genetic research
suggested a potential clinical trial.

He soon realized there had to be a better way. 

Faber then teamed up with former 23andMe executive Nancy Yu to
found RDMD, a platform that works with patients, top experts and
foundations to collect patient data on their history and
symptoms. These records help patients share their data with
doctors, get second opinions, and coordinate ongoing care.
Patients can also give consent to share biomarkers for drug
development and possible clinical trial developments. 

On Monday, RDMD announced $3 million in seed funding led
by Lux
Capital
 and Village
Global
, whose network of backers include Bill Gates,
Mark Zuckerberg, and Jeff Bezos. 

Faber likens RDMD to the “Flatiron
Health
of rare diseases” since it provides a searchable
database for patients, researchers and doctors that makes patient
data usable for research and drug development purposes.

The problem in the rare disease sector is that there aren’t that
many doctors, patients or researchers so it takes a long time to
collect enough clinical data to do research. The goal of RDMD is
to create a platform that can shorten the timeline for research
and development of treatments for rare disease.

“We wanted to bridge the gap between the patient community and
the science community,” said Faber. 

To date, 150 patients have signed up on RDMD for
neurofibromatosis. Although the platform hosts just one rare
disease right now, Yu said that the long-term goal of the company
is to expand to different types of rare diseases. They also hope
to partner with biotech and pharmaceutical companies in the
future. 

See also:


Business Insider Intelligence Exclusive FREE Report: The 5 Ways AI Will Change U.S. Healthcare


Continue Reading
Advertisement Find your dream job

Trending